专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080008749A1 CERAMIDE COMPOSITION AND METHOD OF USE 有权
标题翻译：陶瓷组合物及其使用方法
公开(公告)号：US20080008749A1
公开(公告)日：2008-01-10
申请号：US11773989
申请日：2007-07-06
申请人： Eric Pearlman , Mark Kester
发明人： Eric Pearlman , Mark Kester
IPC分类号： A61K31/195 , A61K31/133 , A61K9/127 , A61K9/14 , A61P27/02
CPC分类号： A61K31/164
摘要： A method for treating and preventing diseases associated with neutrophil infiltration, particularly ocular diseases, is provided, which method comprises administering to a subject in need thereof an effective amount of ceramide or a derivative thereof. Also provided is a composition for treating diseases associated with neutrophil infiltration, the composition comprising ceramide or a derivative thereof.
摘要翻译：提供了治疗和预防与嗜中性粒细胞浸润相关的疾病，特别是眼部疾病的方法，该方法包括向有需要的受试者施用有效量的神经酰胺或其衍生物。还提供了用于治疗与嗜中性粒细胞浸润相关的疾病的组合物，该组合物包含神经酰胺或其衍生物。

2. 发明授权

US10045953B2 Ceramide composition and method of use 有权
公开(公告)号：US10045953B2
公开(公告)日：2018-08-14
申请号：US11773989
申请日：2007-07-06
申请人： Eric Pearlman , Mark Kester
发明人： Eric Pearlman , Mark Kester
IPC分类号： A61K9/127 , A61K31/164
摘要： A method for treating and preventing diseases associated with neutrophil infiltration, particularly ocular diseases, is provided, which method comprises administering to a subject in need thereof an effective amount of ceramide or a derivative thereof. Also provided is a composition for treating diseases associated with neutrophil infiltration, the composition comprising ceramide or a derivative thereof.

3. 发明授权

US08889640B1 Composition and method for the treatment of gastrin mediated cancers 有权
标题翻译：用于治疗胃泌素介导的癌症的组合物和方法
公开(公告)号：US08889640B1
公开(公告)日：2014-11-18
申请号：US12489334
申请日：2009-06-22
申请人： Jill P. Smith , Mark Kester , Gail L. Matters , John F. Harms
发明人： Jill P. Smith , Mark Kester , Gail L. Matters , John F. Harms
IPC分类号： C12N15/11
CPC分类号： C12N15/1136 , C12N2310/14
摘要： Gastrin mRNA down-regulation using either stable transfection of an antisense gastrin cDNA or one of three shRNA (short hairpin RNA) constructs achieves significant reduction in growth of human pancreatic cancer. Tumor growth rate and incidence of metastases in both wild type and transfected pancreatic cancer cells is directly proportional to the degrees of gastrin mRNA expression. In order to avoid rapid degradation of injected siRNA, nanoliposomes can be loaded with gastrin siRNA and used to deliver the siRNA to the tumors. Significant reduction of tumors in mice using siRNA loaded nanoliposomes is achieved. Uptake of pegylated nanoliposomes by tumor cells depends upon the pegylation percentage.
摘要翻译：使用稳定转染反义胃泌素cDNA或三种shRNA（短发夹RNA）构建体之一的胃泌素mRNA下调可显着降低人胰腺癌的生长。野生型和转染的胰腺癌细胞的肿瘤生长速度和转移发生率与胃泌素mRNA表达程度成正比。为了避免注射的siRNA的快速降解，纳豆脂质体可以加载胃泌素siRNA，并用于将siRNA递送至肿瘤。实现使用siRNA负载纳米脂质体的小鼠肿瘤的显着减少。肿瘤细胞对聚乙二醇化纳米脂质体的摄取取决于聚乙二醇化百分比。

4. 发明授权

US08771741B2 In vivo photodynamic therapy of cancer via a near infrared agent encapsulated in calcium phosphate nanoparticles 有权
标题翻译：通过封装在磷酸钙纳米粒子中的近红外线的体内光动力治疗癌症
公开(公告)号：US08771741B2
公开(公告)日：2014-07-08
申请号：US12657556
申请日：2010-01-22
申请人： James H. Adair , Mark Kester , Erhan I. Altinoglu , Brian M. Barth , Timothy J. Russin , James M. D. Kaiser , Thomas T. Morgan , Karen L. Eklund
发明人： James H. Adair , Mark Kester , Peter C. Eklund , Erhan I. Altinoglu , Brian M. Barth , Timothy J. Russin , James M. D. Kaiser , Thomas T. Morgan
IPC分类号： A61K9/14
CPC分类号： A61K41/0057 , A61K9/51 , A61K47/6921 , A61K47/6923
摘要： Nano-encapsulated photosensitizers and their use in the treatment of tumors and/or imaging is described. Preferably, the photosensitizers are encapsulated in a calcium phosphate nanoparticle (CPNP). Encapsulating the PS in a CPNP increases the half-life of the PS, increases absorption of the PS into the target cell tissue, increases the photostability of the PS, increases the photoefficiency of the PS, increases in vivo retention of the PS, or combinations thereof, ultimately making it a highly efficacious agent for use in photodynamic therapy, imaging target tissues, vessels, or tumors, and/or detecting or locating tumors.
摘要翻译：描述了纳米包封的光敏剂及其在治疗肿瘤和/或成像中的用途。优选地，将光敏剂包封在磷酸钙纳米颗粒（CPNP）中。将PS封装在CPNP中增加PS的半衰期，增加PS进入靶细胞组织的吸收，增加PS的光稳定性，增加PS的光效，增加PS的体内保留或组合最终使其成为用于光动力疗法，成像靶组织，血管或肿瘤，和/或检测或定位肿瘤的高效药物。

5. 发明申请

US20100247436A1 In vivo photodynamic therapy of cancer via a near infrared agent encapsulated in calcium phosphate nanoparticles 有权
标题翻译：通过封装在磷酸钙纳米粒子中的近红外线的体内光动力治疗癌症
公开(公告)号：US20100247436A1
公开(公告)日：2010-09-30
申请号：US12657556
申请日：2010-01-22
申请人： James H. Adair , Mark Kester , Peter C. Eklund , Karen L. Eklund , Erhan Altinoglu , Brian M. Barth , Timothy J. Russin , James M.D. Kaiser , Thomas T. Morgan
发明人： James H. Adair , Mark Kester , Peter C. Eklund , Karen L. Eklund , Erhan Altinoglu , Brian M. Barth , Timothy J. Russin , James M.D. Kaiser , Thomas T. Morgan
IPC分类号： A61K49/00 , A61K9/14 , A61K39/395 , A61P35/04 , A61P35/00 , A61M37/00
CPC分类号： A61K41/0057 , A61K9/51 , A61K47/6921 , A61K47/6923
摘要： Nano-encapsulated photosensitizers and their use in the treatment of tumors and/or imaging is described. Preferably, the photosensitizers are encapsulated in a calcium phosphate nanoparticle (CPNP). Encapsulating the PS in a CPNP increases the half-life of the PS, increases absorption of the PS into the target cell tissue, increases the photostability of the PS, increases the photoefficiency of the PS, increases in vivo retention of the PS, or combinations thereof, ultimately making it a highly efficacious agent for use in photodynamic therapy, imaging target tissues, vessels, or tumors, and/or detecting or locating tumors.
摘要翻译：描述了纳米包封的光敏剂及其在治疗肿瘤和/或成像中的用途。优选地，将光敏剂包封在磷酸钙纳米颗粒（CPNP）中。将PS封装在CPNP中增加PS的半衰期，增加PS进入靶细胞组织的吸收，增加PS的光稳定性，增加PS的光效，增加PS的体内保留或组合最终使其成为用于光动力疗法，成像靶组织，血管或肿瘤，和/或检测或定位肿瘤的高效药物。

6. 发明申请

US20050281884A1 Unagglomerated core/shell nanocomposite particles 有权
标题翻译：未凝聚的核/壳纳米复合材料颗粒
公开(公告)号：US20050281884A1
公开(公告)日：2005-12-22
申请号：US11142913
申请日：2005-06-01
申请人： James Adair , Sarah Rouse , Jun Wang , Mark Kester , Christopher Siedlecki , William White , Erwin Vogler , Alan Snyder , Carlo Pantano , Victor Ruiz-Velasco , Lawrence Sinoway
发明人： James Adair , Sarah Rouse , Jun Wang , Mark Kester , Christopher Siedlecki , William White , Erwin Vogler , Alan Snyder , Carlo Pantano , Victor Ruiz-Velasco , Lawrence Sinoway
IPC分类号： A61K9/14 , A61K47/48 , B01J13/02 , C08K9/02
CPC分类号： A61K49/0041 , A61K47/6923 , A61K47/6929 , A61K49/0093 , B01J13/02 , B82Y5/00 , B82Y30/00 , Y10T428/2982 , Y10T428/2984 , Y10T428/2989 , Y10T428/2991 , Y10T428/2995
摘要： The present invention provides a method for the synthesis of unagglomerated, highly dispersed, stable core/shell nanocomposite particles comprised of preparing a reverse micelle microemulsion that contains nanocomposite particles, treating the microemulsion with a silane coupling agent, breaking the microemulsion to form a suspension of the nanocomposite particles by adding an acid/alcohol solution to the microemulsion that maintains the suspension of nanocomposite particles at a pH of between about 6 and 7, and simultaneously washing and dispersing the suspension of nanocomposite particles, preferably with a size exclusion HPLC system modified to ensure unagglomeration of the nanocomposite particles. The primary particle size of the nanocomposite particles can range in diameter from between about 1 to 100 nm, preferably from between about 10 to 50 nm, more preferably about 10 to 20 nm, and most preferably about 20 nm.
摘要翻译：本发明提供了一种用于合成非聚集的，高度分散的，稳定的核/壳纳米复合材料颗粒的方法，其包括制备含有纳米复合颗粒的反胶束微乳液，用硅烷偶联剂处理微乳液，破碎微乳液以形成悬浮液该纳米复合颗粒通过向微乳液中加入酸/醇溶液，将纳米复合材料颗粒的悬浮液保持在约6和7之间的pH，同时洗涤和分散纳米复合颗粒的悬浮液，优选用尺寸排阻HPLC系统修饰为确保纳米复合材料颗粒的团聚。纳米复合材料颗粒的一次粒径可以在约1至100nm之间，优选约10至50nm，更优选约10至20nm，最优选约20nm的范围内。

7. 发明授权

US08747891B2 Ceramide anionic liposome compositions 有权
标题翻译：神经酰胺阴离子脂质体组合物
公开(公告)号：US08747891B2
公开(公告)日：2014-06-10
申请号：US13468578
申请日：2012-05-10
申请人： Mark Kester , Sriram S. Shanmugavelandy , Todd Fox
发明人： Mark Kester , Sriram S. Shanmugavelandy , Todd Fox
IPC分类号： A61K31/475 , A61K9/127 , A61K31/44 , A61K31/7076 , A61P35/00 , B01J13/04
CPC分类号： A61K9/1271 , A61K9/1272 , A61K31/437 , A61K31/44 , A61K31/475 , A61K31/7076
摘要： Described herein are pharmaceutical compositions according to aspects of the present invention which include one or more hydrophilic antineoplastic chemotherapeutics, such as vinca alkyloid antineoplastic chemotherapeutics, encapsulated in ceramide anionic liposomes. Methods of treatment of a subject having cancer using the pharmaceutical compositions are described, along with methods of making ceramide anionic liposomes which encapsulate one or more hydrophilic antineoplastic chemotherapeutics in the aqueous interior of the ceramide anionic liposomes.
摘要翻译：本文描述的是根据本发明的方面的药物组合物，其包括一种或多种亲水性抗肿瘤化学治疗剂，例如包封在神经酰胺阴离子脂质体中的长春花链球菌抗肿瘤化学治疗剂。描述了使用药物组合物治疗患有癌症的受试者的方法，以及在神经酰胺阴离子脂质体的水性内部包封一种或多种亲水性抗肿瘤化学治疗剂的神经酰胺阴离子脂质体的制备方法。

8. 发明申请

US20110129413A1 Bioconjugation of Calcium Phosphosilicate Nanoparticles For Selective Targeting of Cells In Vivo 有权
标题翻译：磷酸钙纳米粒子用于体内细胞选择性靶向的生物缀合
公开(公告)号：US20110129413A1
公开(公告)日：2011-06-02
申请号：US12941719
申请日：2010-11-08
申请人： Thomas T. Morgan , Brian M. Barth , James H. Adair , Rahul Sharma , Mark Kester , Sriram S. Shanmugavelandy , Jill P. Smith , Erhan I. Altinoglu , Gail L. Matters , James M. Kaiser , Christopher McGovern
发明人： Thomas T. Morgan , Brian M. Barth , James H. Adair , Rahul Sharma , Mark Kester , Sriram S. Shanmugavelandy , Jill P. Smith , Erhan I. Altinoglu , Gail L. Matters , James M. Kaiser , Christopher McGovern
IPC分类号： A61K51/12 , C07K14/77 , C07K16/00 , C07K2/00 , C07K7/06 , A61K49/00 , A61K47/42 , A61K47/22 , A61K49/18 , A61K9/14 , B82Y5/00 , B82Y40/00
CPC分类号： A61K49/0093 , A61K41/0057 , A61K47/48861 , A61K47/6923 , A61K49/0034 , A61K49/0043
摘要： Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.
摘要翻译：非聚集的可再吸收的磷酸钙纳米粒子（CPNP）被生物缀合成靶向特定细胞特异性的分子。 CPNPs在正常生理pH下是稳定的颗粒。化疗和成像剂可以与CPNP整体形成，使得它们在CPNP内被分隔。以这种方式，保护试剂免于在正常生理pH下与环境的相互作用。然而，一旦CPNP被摄取，在细胞内的pH值下，CPNP溶解释放药剂。因此，化学治疗或显像剂被递送到特定的细胞并允许这些细胞的治疗和/或成像。使用生物共轭CPNP都限制了全身暴露于药剂的量，并将更高浓度的药剂递送至细胞。生物缀合CPNP的方法和原理通过乳腺癌，胰腺癌和白血病靶向分子的生物缀合的实例来教导。

9. 发明申请

US20070111306A1 SYSTEMS AND METHODS FOR SELECTION AND MAINTENANCE OF HOMOGENEOUS AND PLURIPOTENT HUMAN EMBRYONIC CELLS 失效
标题翻译：用于选择和维持均质和重组人胚胎细胞的系统和方法
公开(公告)号：US20070111306A1
公开(公告)日：2007-05-17
申请号：US11557791
申请日：2006-11-08
申请人： Ugar Salli , Mark Kester , Kent Vrana
发明人： Ugar Salli , Mark Kester , Kent Vrana
IPC分类号： C12N5/08 , C12N5/10
CPC分类号： C12N5/0606 , C12N2500/36 , C12N2501/48
摘要： A number of human disorders are characterized by degeneration or loss of specific cells, resulting in pathology associated with reduction or absence of cell function. Such diseases include neurodegenerative diseases and diabetes. Methods are described for obtaining a substantially homogeneous population of undifferentiated human embryonic stem cells including incubating a population of human embryonic stem cells with an amount of a selection agent. The selection agent is effective to reduce or eliminate differentiated embryonic stem cells from the population of cells such that a substantially homogeneous population of undifferentiated human embryonic stem cells is obtained. The substantially homogeneous population of undifferentiated embryonic stem cells may be produced without use of feeder cells.
摘要翻译：许多人类疾病的特征在于特异性细胞的变性或丧失，导致与减少或不存在细胞功能相关的病理学。这些疾病包括神经变性疾病和糖尿病。描述了用于获得基本均匀的未分化人胚胎干细胞群的方法，包括用一定量的选择剂孵育人胚胎干细胞群。选择剂有效地从细胞群中减少或消除分化的胚胎干细胞，从而获得基本上同质的未分化人胚胎干细胞群。未分化胚胎干细胞的基本上同质的群体可以在不使用饲养细胞的情况下生产。

10. 发明授权

US09149544B2 Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo 有权
标题翻译：钙磷硅酸盐纳米颗粒的生物缀合用于体内细胞的选择性靶向
公开(公告)号：US09149544B2
公开(公告)日：2015-10-06
申请号：US12941719
申请日：2010-11-08
申请人： Thomas T. Morgan , Brian M. Barth , James H. Adair , Rahul Sharma , Mark Kester , Sriram S. Shanmugavelandy , Jill P. Smith , Erhan I. Altinoglu , Gail L. Matters , James M. Kaiser , Christopher McGovern
发明人： Thomas T. Morgan , Brian M. Barth , James H. Adair , Rahul Sharma , Mark Kester , Sriram S. Shanmugavelandy , Jill P. Smith , Erhan I. Altinoglu , Gail L. Matters , James M. Kaiser , Christopher McGovern
IPC分类号： A61K49/00 , A61K41/00 , A61K47/48
CPC分类号： A61K49/0093 , A61K41/0057 , A61K47/48861 , A61K47/6923 , A61K49/0034 , A61K49/0043
摘要： Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.
摘要翻译：非聚集的可再吸收的磷酸钙纳米粒子（CPNP）被生物缀合成靶向特定细胞特异性的分子。 CPNPs在正常生理pH下是稳定的颗粒。化疗和成像剂可以与CPNP整体形成，使得它们在CPNP内被分隔。以这种方式，保护试剂免于在正常生理pH下与环境的相互作用。然而，一旦CPNP被摄取，在细胞内的pH值下，CPNP溶解释放药剂。因此，化学治疗或显像剂被递送到特定的细胞并允许这些细胞的治疗和/或成像。使用生物共轭CPNP都限制了全身暴露于药剂的量，并将更高浓度的药剂递送至细胞。生物缀合CPNP的方法和原理通过乳腺癌，胰腺癌和白血病靶向分子的生物缀合的实例来教导。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式